Clinical Trials Search
Clinical Trial 20178
Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT03909334
Phase: Phase II
Prinicipal Investigator: Andreas Saltos
Study Title
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Summary
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
Objective
Primary Objective: Determine whether, in patients with TKI-naïve locally advanced or metastatic EGFR mutant NSCLC the addition of ramucirumab to osimertinib improves progression free survival, compared to osimertinib alone Secondary Objectives: Determine whether osimertinib plus ramucirumab improves objective response rate (ORR) compared with osimertinib alone. Determine whether osimertinib plus ramucirumab improves overall survival (OS) compared with osimertinib alone. Determine whether osimertinib plus ramucirumab improves disease control rate (DCR) compared with osimertinib alone. Determine the safety and tolerability of combining osimertinib with ramucirumab compared with osimertinib alone.
Therapies
Medications
AZD9291 (Osimertinib); IMC-1121B (Ramucirumab); Osimertinib (); Ramucirumab ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.